Cost-effectiveness of prophylactic indomethacin in very-low-birth-weight infants.
OBJECTIVE
To perform cost-effectiveness analysis to facilitate the decision-making process surrounding use of indomethacin in preterm infants to lower the incidence of patent ductus arteriosus (PDA), intraventricular hemorrhage (IVH), and death.


METHODS
A MEDLINE literature search from 1966 to July 2000 was performed to identify relevant randomized, controlled trials (RCTs), as well as cohort and retrospective case-control studies. A decision tree was built representing the choice to use or not use indomethacin, and the potential outcome costs. Probabilities of being in each chance node were obtained from this search. Where data probabilities were not clear, a sensitivity analysis was conducted.


RESULTS
There was no difference in the expected survival per year; however, there was a significant difference when effectiveness was measured as quality-adjusted life years (QALYs), resulting in 11 and 10 years for the indomethacin and control groups, respectively. The indomethacin treatment cost was $95,157 and that of the control groups was $99,955. The cost effectiveness per life expectancy of being in the indomethacin and control groups was $7142 and $7727, respectively. The sensitivity analysis for PDA closure and prevention of IVH for infants eventually developing PDA versus those without PDA showed no difference. The cost-effectiveness analysis per QALY was $8443 for the indomethacin treatment and $9168 for the control group.


CONCLUSIONS
The prophylactic use of indomethacin is less costly and more effective within an important range of certainty. However, this analysis does not include several potentially confounding factors, such as antenatal steroid use or indomethacin-induced renal toxicity. Depending on the frequency with which these factors arise, economic projections may be considerably altered against the early use of indomethacin.
Moya
Martin P
MP
Department of Pediatrics, Division of Neonatology, Duke University Medical Center, Durham, NC, USA. mmoya@vitametrix.com
Goldberg
Ronald N
RN
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000191:economics* / Q000627:therapeutic use*; D002543:Cerebral Hemorrhage / Q000191:economics / Q000517:prevention & control; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D004374:Ductus Arteriosus, Patent / Q000191:economics / Q000517:prevention & control; D006801:Humans; D007213:Indomethacin / Q000191:economics* / Q000627:therapeutic use*; D007231:Infant, Newborn; D019102:Infant, Very Low Birth Weight; D016239:MEDLINE; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D012680:Sensitivity and Specificity
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007213:Indomethacin